Intervention: Nebulised beta-2 agonist (albuterol, salbutamol) 5mg aerosolised every four hours, compared to placebo (nebulised saline). Outcome: Primary -Ventilator-free days in the 28-day period after achieving unassisted breathing. Secondary -Number of ICU-free and organ-failure free days at 28 days after randomisation; mortality before hospital discharge with unassisted breathing at day 60 and day 90; ventilator-free days and mortality in patients with PaO 2 /FiO 2 <200 mm Hg.
Search terms: Pulmonary oedema; acute respiratory distress syndrome; acute lung injury; alveolar fluid clearance.
The study: Multi-centre, randomised, placebo-controlled trial with intention-to-treat analysis.
The study patients:
The study was stopped after only 288 patients had been recruited due to crossing of pre-defined futility boundaries at interim analysis.
Thirty-three hospitals of the National Heart, Lung, and Blood Institute ARDS Clinical Trials Network were used. Recruitment took place from August 6, 2007 to July 7, 2008. Patients were intubated, receiving mechanical ventilation and met criteria for acute lung injury.
Exclusion criteria: Age <13 years; pregnant; increased ICP; history of severe neuromuscular disease; severe chronic respiratory failure or asthma (requiring beta-2 agonists); comorbidity associated with six-month mortality >50%; burns >40% TBSA; acute MI or ACS within the last 30 days; severe congestive heart failure; heart rate >85% of predicted maximum heart rate; onset of AF requiring anticoagulation; high frequency ventilation; parent team unwilling to use a lung-protective ventilation protocol and fluid-conservative haemodynamic strategy (measured by CVP or PAOP).
Control group: (n=130), no patients lost to follow up or excluded from analysis). An aerosolised, sterile 0.9% sodium chloride placebo was administered every four hours for 10 days after randomisation or for 24 hours after extubation.
Experimental group: (n=152), no patients lost to follow up or excluded from analysis). A standard dose of 5 mg aerosolised salbutamol was administered every four hours for 10 days after randomisation or for 24 hours after extubation.
The results: The trial was stopped early as pre-defined futility boundaries were crossed (discrepancy of -0.4 VFDs between study arms).
EBM questions: 1. Do the methods allow the adequate testing of the hypothesis?
Yes. The trial was well designed but there were some limitations. • Patients with burns >40% TBSA were excluded from the trial; this cohort of patients are more likely to develop ALI. The reason given by the authors was that these patients would be unlikely to survive to the primary endpoint. • A total of 2688 patients were screened but only 282 were included in the study, raising the question of whether the included patients were truly representative.
Do the statistical tests correctly test the results to allow differentiation of statistically significant results? Yes, with the

Aerolised salbutamol in acute lung injury
Aerosolised salbutamol does not improve clinical outcomes in patients with acute lung injury.
Level of evidence: 1B (Individual RCT with a wide confidence interval) We need to consider whether a specific indication for their use is present before prescribing aerosolised beta-2 agonists in mechanically ventilated patients with acute lung injury. The BALTI-2 study, 1 which looked at intravenous beta agonists in acute lung injury, was also stopped early. However BALTI-2 was stopped early due to a significant increase in mortality in the active treatment group. These two trials in combination suggest that beta-2 agonist use in ALI needs careful consideration. More evidence may come from ongoing trials. 12. Should I audit my current practice because of these results?
Yes, to determine what proportion of such patients are receiving nebulised salbutamol routinely on intensive care units. This article was discussed at the Queen Elizabeth Hospital Birmingham Intensive Care Medicine Journal Club.
